Consider aspirin prophylaxis for liver cancer: Aus researchers
Hepatologists have pooled the evidence on the pros and cons for high-risk patients
People at high risk of hepatocellular carcinoma (HCC) should be considered for prophylactic daily aspirin, NSW researchers say.
They believe their systematic review and meta-analysis is the first to examine the HCC-preventive effect of aspirin, other NSAIDs and antiplatelet therapy in people with viral hepatitis B or C, alcoholic liver disease or non-alcoholic steatosis.
Led by gastroenterologist and hepatologist Associate Professor Mark Danta, from Sydney’s St Vincent’s Hospital, the research team found
